Venous Thromboembolism

  • Nicola MaureaEmail author
  • Antonietta Caronna
  • Elie N. Mouhayar
Part of the Current Clinical Pathology book series (CCPATH)


Venous thromboembolism (VTE) is particularly common in cancer patients. Among all patients with VTE, 20% have underlying active malignancy. VTE may be the presenting sign of an occult malignancy, and 10% of patients with idiopathic VTE develop cancer within 2 years. Among hospitalized cancer patients, the cumulative incidence of deep venous thrombosis (DVT) has been reported at 4.6%. On the other hand, up to 50% of cancer patients were found to have evidence of DVT at autopsy. Compared to controls, patients with cancer have a higher risk of first and recurrent VTE, as well as bleeding on anticoagulants.

Currently, the gold standard of VTE treatment is low-molecular-weight heparin, but the results of ongoing trials and a better understanding of bleeding risks related to the pharmacodynamic interaction between direct acting anticoagulants with chemotherapy and better evidence of clinical safety could lead to a change in the therapeutic approach to this pathology.


Venous thromboembolism Cancer Pulmonary embolism DOACs Low-molecular-weight heparin VKAs 


  1. 1.
    Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, MASTER Investigators, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica. 2008;93:273–8. Scholar
  2. 2.
    Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer. 2004;91:92–5. Scholar
  3. 3.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339–46. Scholar
  4. 4.
    Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol). 1999;11:105–10. Scholar
  5. 5.
    Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. Scholar
  6. 6.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4. Scholar
  7. 7.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50. Scholar
  8. 8.
    Kwaan H, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis and cancer. Semin Thromb Hemost. 2003;29:283–90. Scholar
  9. 9.
    Lee AY, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137–45. Scholar
  10. 10.
    Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4(6):465–73. Scholar
  11. 11.
    Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25:173–82. Scholar
  12. 12.
    Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol. 1992;81:480–8. Scholar
  13. 13.
    Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in the woman. Arch Intern Med. 1996;156:1806–10. Scholar
  14. 14.
    Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, et al. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection):e19–26. Scholar
  15. 15.
    Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection):e93–e104. Scholar
  16. 16.
    Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297–303. Scholar
  17. 17.
    Tocchetti CG, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15:482–9. Scholar
  18. 18.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–52. Scholar
  19. 19.
    Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189–204. Scholar
  20. 20.
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7. Scholar
  21. 21.
    Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:81–91. Scholar
  22. 22.
    Escalante CP, Zalpour A, Song J, Richardson MN, Lam T, Halm J, et al. Practice patterns and outcomes of rivaroxaban usage in patients with cancer. J Clin Oncol. 2016;34(26):194. Scholar
  23. 23.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53. Scholar
  24. 24.
    van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;01:762. Scholar
  25. 25.
    Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical practice guideline update 2014. J Clin Oncol. 2015;33:654–6. Scholar
  26. 26.
    Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147:475–83. Scholar
  27. 27.
    Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1:e37–46. Scholar
  28. 28.
    Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72. Scholar
  29. 29.
    Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338:372–80. Scholar
  30. 30.
    Harvey D, Morgan E. Cancer, inflammation, and therapy: effects on cytochrome p450–mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96:449–57. Scholar
  31. 31.
    Trials: NCT 02048865, NCT 02073682, NCT 01708850, and NCT 01727427. [Online] Available at:
  32. 32.
    Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677–86. Scholar
  33. 33.
    Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007;22:997–1002. Scholar
  34. 34.
    Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. Scholar
  35. 35.
    Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114:150–7. Scholar
  36. 36.
    Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–91. Scholar
  37. 37.
    van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJ, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014;12:1116–20. Scholar
  38. 38.
    Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136:582–9. Scholar
  39. 39.
    Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of Hokusai-venous thromboembolism study – methodological implications for clinical trials. J Thromb Haemost. 2013;11:1287–94. Scholar
  40. 40.
    Raskob GE, Van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3:e379–87. Scholar
  41. 41.
    Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24. Scholar
  42. 42.
    Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014;19:82–93. Scholar
  43. 43.
    Schulman S, Shrum J, Majeed A. Management of bleeding complications in patients with cancer on DOACs. Thromb Res. 2016;140(Suppl 1):S142–7. Scholar
  44. 44.
    Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122:2310–7. Scholar
  45. 45.
    Parsad S, Ratain MJ. Drug-drug interactions with oral antineoplastic agents. JAMA Oncol. 2017;3:736–8. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nicola Maurea
    • 1
    Email author
  • Antonietta Caronna
    • 1
  • Elie N. Mouhayar
    • 2
  1. 1.Division of CardiologyIstituto Nazionale Tumori - IRCCS - Fondazione G. PascaleNaplesItaly
  2. 2.Department of Cardiology, Division of Internal MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations